Evidence map›Paper›PMID 36348436›Full record

ReviewJournal of medical case reports2022

Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature.

Sanaz Ahmadi Karvigh, Saeideh Salehizadeh, Fahimeh Vahabizad

Open access · goldAbstract readReviewCase Reports
In one paragraph

Review in Journal of medical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sanaz Ahmadi KarvighDepartment of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Saeideh SalehizadehDepartment of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. S.salehizadeh@yahoo.com.ORCID http://orcid.org/0000-0002-6159-2279
Fahimeh VahabizadDepartment of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Sina Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-leucine-rich glioma-inactivated 1 encephalitis is a newly emerged entity characterized by frequent faciobrachial dystonic seizures and a wide spectrum of subacute clinical symptoms such as other seizure types, mood and behavioral changes, and memory loss. We should be aware of differentiating this diagnosis from psychogenic nonepileptic seizures. Mesial temporal, limbic structures, and basal ganglia are the most commonly involved regions. CASE PRESENTATION: Here we review the available data, and report on two young Iranian (White) females, 24 and 18 years old, who represent distinct aspects of the disease. The clinical presentation and degree of tissue involvement varies to some extent in the two reported cases. Case 1 had prominent neuropsychiatric symptoms and suffered from frequent faciobrachial dystonic seizures with more significant basal ganglia involvement, whereas case 2 suffered from severe memory decline and dialeptic seizures along with mesial temporal involvement. Symptoms were refractory to usual treatment and prompt immunotherapy was needed.

conclusionsThis disease has a rather favorable outcome provided that treatment is initiated early. However, resistance to first-line treatment, relapses, and long-term complications highlight the need to establish reliable biomarkers to distinguish different subtypes of this disorder to predict the clinical outcome and prognosis, and to refine management.

Indexed as

EncephalitisGliomaLimbic EncephalitisAutoantibodiesFemaleHumansIntracellular Signaling Peptides and ProteinsIranLeucineNeoplasm Recurrence, LocalSeizuresAutoantibodiesIntracellular Signaling Peptides and ProteinsLeucineAutoimmune encephalitisBasal gangliaFaciobrachial dystonic seizure (FBDS)ImmunotherapyLGI1Rituximab

Identifiers

PMID36348436
PMCPMC9644483
OpenAlexW4308559056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.